ES2377720T3 - Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. - Google Patents

Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. Download PDF

Info

Publication number
ES2377720T3
ES2377720T3 ES03784738T ES03784738T ES2377720T3 ES 2377720 T3 ES2377720 T3 ES 2377720T3 ES 03784738 T ES03784738 T ES 03784738T ES 03784738 T ES03784738 T ES 03784738T ES 2377720 T3 ES2377720 T3 ES 2377720T3
Authority
ES
Spain
Prior art keywords
epha2
methods
antibodies
cancer
sticos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03784738T
Other languages
English (en)
Inventor
Michael S. Kinch
Kelly Carles-Kinch
Jane C. Stewart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Purdue Research Foundation
Original Assignee
MedImmune LLC
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC, Purdue Research Foundation filed Critical MedImmune LLC
Application granted granted Critical
Publication of ES2377720T3 publication Critical patent/ES2377720T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Abstract

Un anticuerpo aislado que específicamente se une al EphA2 y produce la fosforilación del EphA2, donde: a. el anticuerpo compite por unirse al EphA2 con el anticuerpo producido por el hibridoma depositado en la American Type Culture Collection (ATCC) con nº de registro PTA-4380; b. el anticuerpo compite por unirse al EphA2 con el anticuerpo producido por el hibridoma depositado en la ATCC con nº de registro PTA-4381; c. el anticuerpo se produce por el hibridoma depositado en la ATCC con nº de registro PTA-4380;d. el anticuerpo se produce por el hibridoma depositado en la ATCC con nº de registro PTA-4381;e. el anticuerpo se compone de una cadena VH que consta de la secuencia de aminoácidos SEQ ID NO:5 y de una cadena VL que consta de la secuencia de aminoácidos SEQ ID NO:1; f. el anticuerpo se compone de una VL CDR1 que tiene una secuencia de aminoácidos SEQ ID NO:2, de una VL CDR2 que tiene una secuencia de aminoácidos SEQ ID NO:3, de una VL CDR3 que tiene una secuencia de aminoácidos SEQ ID NO:4, de una VH CDR1 que tiene una secuencia de aminoácidos SEQ ID NO: 6, de una VH CDR2 que tiene una secuencia de aminoácidos SEQ ID NO:7, y de una VH CDR3 que tiene una secuencia de aminoácidos SEQ ID NO:8; o g. el anticuerpo se compone de una VL CDR1 que tiene una secuencia de aminoácidos SEQ ID NO:2, de una VL CDR2 que tiene una secuencia de aminoácidos SEQ ID NO:3, de una VL CDR3 que tiene una secuencia de aminoácidos SEQ ID NO:4, de una VH CDR1 que tiene una secuencia de aminoácidos SEQ ID NO:6, de una VH CDR2 que tiene una secuencia de aminoácidos SEQ ID NO:7, y de una VH CDR3 que tiene una secuencia de aminoácidos SEQ ID NO:8, donde una o más de las CDRs tiene una, dos o tres mutaciones.
ES03784738T 2002-05-10 2003-05-12 Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos. Expired - Lifetime ES2377720T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US37936802P 2002-05-10 2002-05-10
US379368P 2002-05-10
US41820402P 2002-10-14 2002-10-14
US418204P 2002-10-14
US46035803P 2003-04-03 2003-04-03
US460358P 2003-04-03
PCT/US2003/015046 WO2004014292A2 (en) 2002-05-10 2003-05-12 EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF

Publications (1)

Publication Number Publication Date
ES2377720T3 true ES2377720T3 (es) 2012-03-30

Family

ID=31721472

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03784738T Expired - Lifetime ES2377720T3 (es) 2002-05-10 2003-05-12 Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.

Country Status (8)

Country Link
US (3) US20040091486A1 (es)
EP (1) EP1575509B1 (es)
JP (1) JP4585968B2 (es)
AT (1) ATE530577T1 (es)
AU (2) AU2003276832A1 (es)
CA (1) CA2485548A1 (es)
ES (1) ES2377720T3 (es)
WO (1) WO2004014292A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
AU2003276832A1 (en) * 2002-05-10 2004-02-25 Medimmune, Llc EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
CA2486615A1 (en) 2002-05-23 2003-12-04 Purdue Research Foundation Low molecular weight protein tyrosine phosphatase (lmw-ptp) as a diagnostic and therapeutic target
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1605961A4 (en) 2003-03-12 2009-11-11 Vasgene Therapeutics Inc POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
KR20110094361A (ko) 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
EP2266628A3 (en) 2003-05-13 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Method of determining the susceptibility to bone meatastases by EPhA2 expression
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
CA2546763A1 (en) * 2003-11-20 2005-06-09 Medimmune, Inc. Epha2 agonistic monoclonal antibodies and methods of use thereof
US20050153923A1 (en) * 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
ATE492564T1 (de) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
US20100009928A1 (en) * 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
AU2005249360B2 (en) 2004-04-12 2011-07-21 Medimmune, Llc Anti-IL-9 antibody formulations and uses thereof
US7659374B2 (en) 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
AU2005286662B2 (en) 2004-09-23 2011-10-06 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2006045110A2 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
US20060121042A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
CA2585671A1 (en) * 2004-10-27 2006-05-04 Medimmune, Inc. Use of modulators of epha2 and ephrina1 for the treatment and prevention of infections
CN104059150B (zh) 2005-02-04 2018-10-02 宏观基因有限公司 结合epha2的抗体及其使用方法
WO2007002543A2 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
WO2007075706A2 (en) * 2005-12-21 2007-07-05 Medimmune, Inc. Affinity optimized epha2 agonistic antibodies and methods of use thereof
CN101622276B (zh) 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
AU2008265928A1 (en) * 2007-06-18 2008-12-24 Medimmune, Llc Synergistic treatment of cells that express EphA2 and ErbB2
JP2010531878A (ja) 2007-06-27 2010-09-30 マリン ポリマー テクノロジーズ，インコーポレーテッド ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP5749009B2 (ja) 2007-08-13 2015-07-15 バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤
DK2199390T3 (en) 2007-08-30 2017-04-03 Daiichi Sankyo Co Ltd ANTI-EphA2 ANTIBODY
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
CN103237901B (zh) 2010-03-01 2016-08-03 卡里斯生命科学瑞士控股有限责任公司 用于治疗诊断的生物标志物
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US9220772B2 (en) 2010-07-22 2015-12-29 The Regents Of The University Of California Anti-tumor antigen antibodies and methods of use
SG190990A1 (en) 2010-12-08 2013-07-31 Stem Centrx Inc Novel modulators and methods of use
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CA2863834A1 (en) 2012-02-06 2013-08-15 Inhibrx Llc Cd47 antibodies and methods of use thereof
CA2900468A1 (en) * 2013-02-06 2014-08-14 Inhibrx Llc Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
BR112015021462A2 (pt) 2013-03-06 2017-10-10 Adimab Llc anticorpos biespecíficos anti-c-met tandem fc
BR112016010051A2 (pt) 2013-11-04 2017-12-05 Pfizer ?conjugados de anticorpo-fármaco anti-efna4?
FR3025717A1 (fr) * 2014-09-16 2016-03-18 Univ Lille Sciences Tech Utilisation conjointe d'un inhibiteur de trka et d'un inhibiteur de epha2 pour une utilisation dans le traitement de cancers
EP3221351A4 (en) 2014-11-19 2018-06-27 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
US10197563B2 (en) 2015-11-10 2019-02-05 New Jersey Institute Of Technology 3-D in vitro model for breast cancer dormancy
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US31252A (en) * 1861-01-29 Improvement in iron ties for cotton-bales
US436782A (en) * 1890-09-23 Process of preparing carbonated beverages
US952560A (en) * 1909-06-28 1910-03-22 Gewerkschaft Der Stein Kohlenzeche Mont Cenis Process of obtaining ammonium sulfate from gases.
US1131262A (en) * 1914-07-31 1915-03-09 Frank Orth Regenerator for furnaces.
US4472371A (en) * 1979-10-29 1984-09-18 Summa Medical Corporation Radiolabeled antibody to anti-tumor associated antigen and process
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5001225A (en) * 1986-12-08 1991-03-19 Georgetown University Monoclonal antibodies to a pan-malarial antigen
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4885238A (en) * 1987-10-30 1989-12-05 The United States Of America As Represented By The Department Of Health And Human Services Immortalized human bronchial epitherial mesothelial cell lines
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
WO1992010591A1 (en) 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69228300T2 (de) * 1991-08-22 1999-09-23 Becton Dickinson Co Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung
ATE249840T1 (de) * 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5837448A (en) * 1992-05-15 1998-11-17 The Salk Institute For Biological Studies Protein-tyrosine kinase genes
CA2149333C (en) * 1992-11-13 2002-01-22 Timothy D. Bartley Eck receptor ligands
JP3560609B2 (ja) * 1992-11-13 2004-09-02 イミュネックス・コーポレーション Ｅｌｋリガンドと呼ばれる新規なサイトカイン
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5516658A (en) * 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5814479A (en) * 1994-01-04 1998-09-29 Zhou; Renping Bsk receptor-like tyrosine kinase
AU702522B2 (en) * 1994-04-15 1999-02-25 Amgen, Inc. HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
US5864020A (en) * 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
CN1117155C (zh) 1994-07-29 2003-08-06 史密丝克莱恩比彻姆有限公司 新型化合物
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
US5798448A (en) * 1994-10-27 1998-08-25 Genentech, Inc. AL-1 neurotrophic factor antibodies
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US5876949A (en) * 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same
US5795775A (en) * 1996-09-26 1998-08-18 Becton Dickinson And Company Culture vessel and assembly
US5761934A (en) * 1996-10-22 1998-06-09 Kuo; Li-Tsao Cable lock and an universal hold-down support
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
US6555321B1 (en) * 1997-08-19 2003-04-29 Vanderbilt University Methods for determining cell responses through EphB receptors
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6696550B2 (en) * 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
IL142921A0 (en) * 1998-11-20 2002-04-21 Genentech Inc USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
CA2380888A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Treatment of metastatic disease
CA2382655A1 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Antibodies as a cancer diagnostic
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US6245320B1 (en) * 1999-09-01 2001-06-12 University Of Maryland Inhibition of mucin release from airway goblet cells by polycationic peptides
AU4139801A (en) * 1999-12-06 2001-06-12 Board Of Trustees Of The University Of Arkansas, The Controlled delivery of antigens
ATE474854T1 (de) * 2000-01-27 2010-08-15 Medimmune Llc Rsv neutralisierende antikörper mit sehr hohen affinität
EP2341075A1 (en) * 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
BR0109704A (pt) * 2000-03-31 2003-04-29 Purdue Research Foundation Método de tratamento usando conjugados de imunógeno ligando
JP5305553B2 (ja) * 2000-10-12 2013-10-02 ユニバーシティー オブ ロチェスター 癌細胞の増殖を阻害する組成物
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) * 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
ES2727425T3 (es) * 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
EP1410011B1 (en) * 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
US7164007B2 (en) * 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
AU2003276832A1 (en) * 2002-05-10 2004-02-25 Medimmune, Llc EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
JP2005533861A (ja) * 2002-07-25 2005-11-10 メデュームン，インコーポレーテッド 抗ＲＳＶ、抗ｈＭＰＶ、および抗ＰＩＶ抗体を使用するＲＳＶ、ｈＭＰＶ、およびＰＩＶの治療法と予防法
AU2003278725A1 (en) * 2002-08-27 2004-03-19 Bristol-Myers Squibb Company Polynucleotide predictor set for identifying protein tyrosine kinase modulators
JP2006507256A (ja) * 2002-09-24 2006-03-02 ザ バーナム インスティチュート Ｅｐｈ受容体活性を調節する新規薬剤
US20050059592A1 (en) * 2003-04-11 2005-03-17 Kiener Peter A. EphA2 and hyperproliferative cell disorders
KR20110094361A (ko) * 2003-04-11 2011-08-23 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
AU2004229527B2 (en) * 2003-04-11 2009-08-20 Medimmune, Llc Methods of preventing or treating respiratory conditions
CA2546763A1 (en) * 2003-11-20 2005-06-09 Medimmune, Inc. Epha2 agonistic monoclonal antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2009239780B2 (en) 2011-03-17
EP1575509A2 (en) 2005-09-21
EP1575509B1 (en) 2011-10-26
JP4585968B2 (ja) 2010-11-24
AU2003276832A1 (en) 2004-02-25
US20040091486A1 (en) 2004-05-13
WO2004014292A2 (en) 2004-02-19
ATE530577T1 (de) 2011-11-15
US20070086943A1 (en) 2007-04-19
JP2006507013A (ja) 2006-03-02
WO2004014292A3 (en) 2006-02-16
US20100298545A1 (en) 2010-11-25
AU2009239780A1 (en) 2009-12-10
EP1575509A4 (en) 2007-04-25
CA2485548A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
ES2377720T3 (es) Anticuerpos monoclonales agon�?sticos epha2 y métodos de uso de los mismos.
WO2005051307A3 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
CL2008001813A1 (es) Compuestos derivados de quinolin-3-carbonitrilo sustituidos con piperazina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis, inflamacion, cancer entre otras (div. sol. 266-04).
BRPI0511420A (pt) fosforodiamidatos de sulfoniletila
NL300418I1 (nl) Gebruik van trifunctionele bispecifieke en trispecifieke antilichamen voor de behandeling van maligne ascitis
BRPI0518228A (pt) inibidores de cinesina mitótica e métodos de uso destes
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
UY28342A1 (es) Nuevos compuestos
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA200500893A1 (ru) Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
BR0316296A (pt) Compostos lapacone e seus métodos de uso
BRPI0515721A (pt) uso de um inibidor de src cinase e um inibidor de bcr-abl, composição farmacêutica e combinação
NO20055612L (no) Anti-inflammatoriske fosfonatforbindelser
WO2007075706A3 (en) Affinity optimized epha2 agonistic antibodies and methods of use thereof
AR037756A1 (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
WO2019006002A8 (en) Methods of treating cancer with small molecule nf-kb inhibitors
TR200302193T4 (tr) Kombinasyon kemoterapisi.
NO20065473L (no) IL-6RL/IL-6-kimaerer for terapi av kjemoterapeutisk indusert perifer nevropati.
EA200701835A1 (ru) Амидные производные в качестве лигандов ионных каналов, их фармацевтические композиции и способы их применения
GB0305928D0 (en) Organic compounds